Balchem 과거 순이익 실적
과거 기준 점검 5/6
Balchem은 연평균 11.7%의 비율로 수입이 증가해 온 반면, Chemicals 산업은 수입이 3.8% 감소했습니다. 매출은 연평균 5.6%의 비율로 증가했습니다. Balchem의 자기자본이익률은 12.6%이고 순이익률은 15.1%입니다.
핵심 정보
11.68%
순이익 성장률
11.61%
주당순이익(EPS) 성장률
| Chemicals 산업 성장률 | 12.93% |
| 매출 성장률 | 5.60% |
| 자기자본이익률 | 12.62% |
| 순이익률 | 15.14% |
| 최근 순이익 업데이트 | 30 Jun 2026 |
최근 과거 실적 업데이트
Recent updates
내러티브 업데이트 • Aug 04
BCPC: Record Earnings And Buybacks Will Support Strong Future Returns
Analysts have raised their price target for Balchem to $207.00 from $200.75, reflecting updated assumptions around discount rates, revenue growth, profit margins and future P/E expectations. What’s in the News for Balchem Balchem reported record Q2 2026 net sales, net earnings, and adjusted EBITDA, with revenue at US$284.0 million.Seeking Alpha • Aug 02
Balchem: It's A Buy From Me After Posting Strong Q2 Results
Summary Balchem Corporation posted Q2 results, with EPS of $1.49 beating estimates by $0.07, while surpassing the consensus by $15M and was up 11% YoY. All areas of the business posted impressive results, as the minimum revenue growth for a segment was 8.9%, while the peak was 15% in Animal Nutrition & Health. The stock appears to be trading for a ~9% discount to its fair value right now based on my FCF valuation model. Read the full article on Seeking Alpha내러티브 업데이트 • Jun 26
BCPC: Share Repurchases And Strong Margins Will Support Future Returns
Analysts have lifted their Balchem fair value estimate from $191 to about $200.75, citing updates to their models that include revised assumptions for revenue growth, profit margins, the discount rate, and Balchem's future P/E multiple. What’s in the News for Balchem Balchem reported that from January 1, 2026 to March 31, 2026, the company repurchased 89,880 shares, representing 0.28% of its shares, for US$14.92 million under its existing buyback program.
새로운 내러티브 • Mar 13
Long-Term Nutrition And Health Trends Will Support Stronger Margins And Earnings Potential
Catalysts About Balchem Balchem supplies specialty nutrients and ingredients for human, animal and plant health, along with performance gases and related solutions. What are the underlying business or industry changes driving this perspective?
새로운 내러티브 • Feb 26
Encapsulation Investments And International Expansion Will Shape Balanced Future For Nutrition Specialist
Catalysts About Balchem Balchem produces specialty nutrition and ingredient solutions for human, animal and plant health, along with performance gases. What are the underlying business or industry changes driving this perspective?내러티브 업데이트 • Feb 17
BCPC: Dividend Increase And Buyback Program Will Support Steady Future Returns
Analysts kept their Balchem fair value estimate broadly steady at $191, pointing to only very small tweaks in assumptions such as discount rate, long term revenue growth, profit margin and future P/E as the basis for maintaining their target level. What's in the News On December 9, 2025, Balchem Corporation's Board of Directors declared an annual dividend of $0.96 per share, payable on January 20, 2026, to stockholders of record as of December 23, 2025.분석 기사 • Feb 15
If EPS Growth Is Important To You, Balchem (NASDAQ:BCPC) Presents An Opportunity
The excitement of investing in a company that can reverse its fortunes is a big draw for some speculators, so even...내러티브 업데이트 • Feb 03
BCPC: Share Repurchases And Higher Dividend Will Support Attractive Future Returns
Analysts have maintained their fair value estimate for Balchem at US$191. They have made only minimal adjustments to the discount rate, revenue growth, profit margin, and future P/E assumptions, indicating that their overall view on the stock's valuation drivers remains essentially unchanged.분석 기사 • Feb 01
Is Now An Opportune Moment To Examine Balchem Corporation (NASDAQ:BCPC)?
Balchem Corporation ( NASDAQ:BCPC ), is not the largest company out there, but it saw a decent share price growth of...내러티브 업데이트 • Jan 20
BCPC: Share Repurchases And Rising Dividend Will Support Attractive Future Returns
Analysts have maintained their Balchem fair value estimate at US$191, with only small tweaks to the discount rate, revenue growth, profit margin, and forward P/E assumptions. This reflects a largely unchanged view on the stock's risk and earnings profile.내러티브 업데이트 • Jan 05
BCPC: Share Repurchases And Dividend Increases Will Support Attractive Future Returns
Analysts kept their fair value estimate for Balchem steady at US$191, pointing to only very small model tweaks in the discount rate, revenue growth, margin and forward P/E assumptions rather than any change in their overall view of the company. What's in the News Balchem Corporation announced a share repurchase program authorizing the company to buy back up to 4,000,000 shares, with no expiration date on the program (Key Developments).내러티브 업데이트 • Dec 20
BCPC: Share Repurchases And Dividend Increases Will Drive Attractive Future Returns
Analysts have maintained their price target on Balchem at approximately $191.00. This reflects only marginal tweaks to underlying assumptions such as discount rate, revenue growth, and profit margin, rather than a material change in their outlook.내러티브 업데이트 • Dec 06
BCPC: Share Repurchases Will Support Attractive Long Term Return Potential
Analysts have lowered their price target on Balchem by approximately $9 to about $191 per share, reflecting more cautious assumptions around revenue growth and profit margins, even though long term valuation multiples are slightly higher. What's in the News Completed a long running share repurchase program, buying back a total of 3,475,622 shares, or about 12.76% of shares outstanding, for approximately $190.58 million since the authorization began in 1999 (Key Developments) During the most recent quarter from July 1, 2025 to September 30, 2025, repurchased 95,760 shares, roughly 0.3% of shares outstanding, for $15.42 million as the final tranche under the existing buyback plan (Key Developments) Valuation Changes The Fair Value Estimate has fallen modestly from about $200.33 to $191.00 per share, reflecting a slightly more conservative outlook.분석 기사 • Dec 01
Balchem (NASDAQ:BCPC) Is Experiencing Growth In Returns On Capital
If we want to find a potential multi-bagger, often there are underlying trends that can provide clues. Amongst other...분석 기사 • Oct 10
Some Shareholders Feeling Restless Over Balchem Corporation's (NASDAQ:BCPC) P/E Ratio
Balchem Corporation's ( NASDAQ:BCPC ) price-to-earnings (or "P/E") ratio of 31.9x might make it look like a strong sell...분석 기사 • Sep 26
Balchem (NASDAQ:BCPC) Could Easily Take On More Debt
Howard Marks put it nicely when he said that, rather than worrying about share price volatility, 'The possibility of...분석 기사 • Aug 26
Estimating The Fair Value Of Balchem Corporation (NASDAQ:BCPC)
Key Insights Using the 2 Stage Free Cash Flow to Equity, Balchem fair value estimate is US$174 With US$162 share price...Seeking Alpha • Oct 28
Balchem's Q3 Shows Record Earnings And Valuation Pressure
Summary Balchem Corporation shows strong long-term growth potential in high-margin segments and product innovation, but faces challenges in Animal Nutrition & Health and rising costs. Balchem's financial momentum in Q3 2024 includes record earnings, improved margins, and significant debt reduction, despite missing revenue estimates. BCPC stock's high P/E ratio of 39.82x suggests big market expectations, but the current valuation may be too high given existing challenges. I rate Balchem as a “Hold” due to high valuation, operational challenges, and potential seasonal slowdown, advising cautious investors to wait for a better entry point. Read the full article on Seeking Alpha
새로운 내러티브 • Aug 29
Innovating In Nutrition And Health Sectors Drives Strong Financial Growth And Market Expansion
Launch of Optifolin+ in the nutrition segment and strong Human Nutrition & Health sales indicate potential for market share expansion and sustained revenue growth.Seeking Alpha • May 10
Balchem: A Tale Of Two Businesses
Summary Balchem Corporation's Q1 2024 earnings surpassed expectations, but the company's full-year bottom-line expansion could be slower than what it achieved for the first quarter. The Human Nutrition & Health segment is riding on the supplements market's growth, while the Animal Nutrition & Health segment is encountering stiff competition in the European animal feed market. It is a tale of two businesses for BCPC, which implies that the stock warrants a Neutral or Hold rating. Read the full article on Seeking AlphaSeeking Alpha • Feb 21
Balchem: Potential Turnaround Is In The Price
Summary Balchem registered a -2.5% top-line miss for the fourth quarter of 2023, which is attributable to the underperformance of its Animal Nutrition business. BCPC is well-positioned to achieve positive top line and earnings expansion in the current year, but I deem the stock's valuations to be fair. The Company continues to be rated as a Hold, as my opinion is that the expected 2024 turnaround for BCPC is priced in. Read the full article on Seeking Alpha매출 및 비용 세부 내역
매출 및 비용 세부 내역
Balchem가 돈을 벌고 사용하는 방법. 최근 발표된 LTM 실적 기준.
순이익 및 매출 추이
| 날짜 | 매출 | 순이익 | 일반관리비 | 연구개발비 |
|---|---|---|---|---|
| 30 Jun 26 | 1,086 | 164 | 152 | 20 |
| 31 Mar 26 | 1,057 | 158 | 150 | 20 |
| 31 Dec 25 | 1,037 | 155 | 143 | 19 |
| 30 Sep 25 | 1,014 | 149 | 140 | 18 |
| 30 Jun 25 | 986 | 143 | 137 | 18 |
| 31 Mar 25 | 965 | 137 | 133 | 17 |
| 31 Dec 24 | 954 | 128 | 136 | 17 |
| 30 Sep 24 | 942 | 122 | 144 | 16 |
| 30 Jun 24 | 932 | 117 | 139 | 16 |
| 31 Mar 24 | 930 | 115 | 131 | 16 |
| 31 Dec 23 | 922 | 109 | 120 | 15 |
| 30 Sep 23 | 926 | 103 | 117 | 14 |
| 30 Jun 23 | 941 | 99 | 122 | 13 |
| 31 Mar 23 | 946 | 99 | 126 | 12 |
| 31 Dec 22 | 942 | 105 | 121 | 12 |
| 30 Sep 22 | 923 | 109 | 116 | 14 |
| 30 Jun 22 | 877 | 109 | 109 | 14 |
| 31 Mar 22 | 842 | 102 | 107 | 14 |
| 31 Dec 21 | 799 | 96 | 102 | 14 |
| 30 Sep 21 | 767 | 93 | 100 | 11 |
| 30 Jun 21 | 744 | 90 | 100 | 11 |
| 31 Mar 21 | 715 | 88 | 99 | 10 |
| 31 Dec 20 | 704 | 85 | 102 | 10 |
| 30 Sep 20 | 689 | 83 | 104 | 11 |
| 30 Jun 20 | 673 | 82 | 104 | 11 |
| 31 Mar 20 | 661 | 81 | 102 | 11 |
| 31 Dec 19 | 644 | 80 | 95 | 11 |
| 30 Sep 19 | 641 | 80 | 89 | 12 |
| 30 Jun 19 | 637 | 78 | 84 | 12 |
| 31 Mar 19 | 639 | 78 | 82 | 12 |
| 31 Dec 18 | 644 | 79 | 84 | 12 |
| 30 Sep 18 | 639 | 100 | 83 | 11 |
| 30 Jun 18 | 635 | 97 | 84 | 11 |
| 31 Mar 18 | 618 | 94 | 81 | 10 |
| 31 Dec 17 | 595 | 90 | 81 | 9 |
| 30 Sep 17 | 576 | 64 | 82 | 9 |
| 30 Jun 17 | 564 | 62 | 82 | 8 |
| 31 Mar 17 | 556 | 60 | 82 | 7 |
| 31 Dec 16 | 553 | 56 | 83 | 7 |
| 30 Sep 16 | 545 | 56 | 77 | 7 |
| 30 Jun 16 | 547 | 56 | 76 | 7 |
| 31 Mar 16 | 543 | 56 | 72 | 6 |
| 31 Dec 15 | 552 | 60 | 68 | 6 |
| 30 Sep 15 | 582 | 63 | 71 | 6 |
양질의 수익: BCPC는 고품질 수익을 보유하고 있습니다.
이익 마진 증가: BCPC의 현재 순 이익률 (15.1%)은 지난해 (14.5%)보다 높습니다.
잉여현금흐름 대비 순이익 분석
과거 순이익 성장 분석
수익추이: BCPC의 수익은 지난 5년 동안 연평균 11.7% 증가했습니다.
성장 가속화: 지난 1년간 BCPC 의 수익 증가율(15.2%)은 연간 평균(11.7%)을 초과합니다.
수익 대 산업: BCPC의 지난 1년 수익 증가율(15.2%)은 Chemicals 업계의 -4%를 상회했습니다.
자기자본이익률
높은 ROE: BCPC의 자본 수익률(12.6%)은 낮음으로 평가됩니다.
총자산이익률
투하자본수익률
우수한 과거 실적 기업을 찾아보세요
기업 분석 및 재무 데이터 상태
| 데이터 | 최종 업데이트 (UTC 시간) |
|---|---|
| 기업 분석 | 2026/08/04 16:56 |
| 종가 | 2026/08/04 00:00 |
| 수익 | 2026/06/30 |
| 연간 수익 | 2025/12/31 |
데이터 소스
당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.
| 패키지 | 데이터 | 기간 | 미국 소스 예시 * |
|---|---|---|---|
| 기업 재무제표 | 10년 |
| |
| 분석가 컨센서스 추정치 | +3년 |
|
|
| 시장 가격 | 30년 |
| |
| 지분 구조 | 10년 |
| |
| 경영진 | 10년 |
| |
| 주요 개발 | 10년 |
|
* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.
별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.
분석 모델 및 스노우플레이크
이 보고서를 생성하는 데 사용된 분석 모델의 세부 정보는 당사의 GitHub 페이지에서 확인하실 수 있습니다. 또한 보고서 사용 방법에 대한 가이드와 YouTube 튜토리얼도 제공하고 있습니다.
Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.
산업 및 섹터 지표
산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.
분석가 소스
Balchem Corporation는 9명의 분석가가 다루고 있습니다. 이 중 4명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
| 분석가 | 기관 |
|---|---|
| Robert Labick | CJS Securities, Inc. |
| Timothy Ramey | D.A. Davidson & Co. |
| Raghuram Selvaraju | H.C. Wainwright & Co. |